Anzeige
Meldung des Tages: Insider kaufen kräftig zu – 421.670 CAD an Käufen, während Silber $88 erreicht

Palatin Technologies News

Aktie
WKN:  A41E9H ISIN:  US6960776010 US-Symbol:  PTN Branche:  Biotechnologie Land:  USA
23,50 $
+1,46 $
+6,62%
20,584 € 13.03.26
Depot/Watchlist
Marktkapitalisierung *
331,16 Mio. €
Streubesitz
88,79%
KGV
-
Index-Zuordnung
-

Palatin Technologies News

25.03.25 - PR Newswire
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency PR Newswire
13.02.25 - PR Newswire
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire
10.02.25 - PR Newswire
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025 PR Newswire
07.02.25 - PR Newswire
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
06.02.25 - PR Newswire
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide PR Newswire
28.01.25 - PR Newswire
Palatin Provides Update on Anticipated 2025 Corporate Milestones
Palatin Provides Update on Anticipated 2025 Corporate Milestones PR Newswire
19.12.24 - PR Newswire
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy PR Newswire
16.12.24 - PR Newswire
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds PR Newswire
25.11.24 - PR Newswire
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis PR Newswire
14.11.24 - PR Newswire
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire
08.11.24 - PR Newswire
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 PR Newswire
04.11.24 - PR Newswire
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 PR Newswire
31.10.24 - PR Newswire
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-​Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity PR Newswire
24.10.24 - PR Newswire
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium PR Newswire
23.10.24 - PR Newswire
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium PR Newswire
07.10.24 - PR Newswire
Palatin Receives Notice of Non-Compliance from NYSE American
Palatin Receives Notice of Non-​Compliance from NYSE American PR Newswire
01.10.24 - PR Newswire
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones PR Newswire
26.09.24 - PR Newswire
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results PR Newswire
09.09.24 - PR Newswire
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones PR Newswire
28.08.24 - PR Newswire
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) PR Newswire

Newssuche

Videos

newspaper
13.03.26 -4,81%
Technical Trading: Kurzfristig Gold Long
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »